Clinical analysis of allogeneic hematopoietic stem cell transplantation for seven cases of acute myeloid leukemia with BCR::ABL1 fusion
10.3760/cma.j.issn.0253-2727.2023.12.005
- VernacularTitle:异基因造血干细胞移植治疗急性髓系白血病伴BCR::ABL1融合基因7例临床分析
- Author:
Mengze HAO
1
;
Xiaoli ZHAO
;
Xiaoyu ZHANG
;
Yuanyuan SHI
;
Ming GONG
;
Lining ZHANG
;
Shulian CHEN
;
Jialin WEI
;
Yi HE
;
Sizhou FENG
;
Mingzhe HAN
;
Erlie JIANG
Author Information
1. 中国医学科学院血液病医院（中国医学科学院血液学研究所），实验血液学国家重点实验室，国家血液系统疾病临床医学研究中心，细胞生态海河实验室，天津 300020
- Keywords:
Acute myeloid leukemia;
Fusion gene, BCR::ABL1;
Allogeneic hematopoietic stem cell transplantation
- From:
Chinese Journal of Hematology
2023;44(12):995-1000
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) patients with BCR::ABL1 fusion.Methods:The clinical data of seven AML patients with BCR::ABL1 fusion from November 2012 to January 2022 were retrospectively analyzed, and their survival status was followed up.Results:The median age of patients at the time of diagnosis was 35 years. Four cases (57.1%) were diagnosed with high leukocyte counts. All cases were assayed as BCR::ABL1 positive and accompanied by four types of gene mutations (NPM1, RUNX1, ASXL1, PHF6) . Seven patients received tyrosine kinase inhibitor (TKI) combined with induction chemotherapy and bridged to allo-HSCT, and six patients received maintenance therapy with TKI. Before allo-HSCT, six patients achieved complete remission, and four patients achieved complete molecular remission (CMR) . After allo-HSCT, the three remaining cases also achieved CMR. All patients were in remission post-allo-HSCT. One case died of infection, and the remaining cases survived without relapse. The 3-year cumulative overall survival rate was (80.0±17.9) %.Conclusions:TKI combined with traditional chemotherapy could achieve a high response rate in AML patients with BCR::ABL1 fusion. In addition, allo-HSCT could enhance the molecular response rate. Maintenance therapy post-HSCT with TKI could improve prognosis.
